{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:20:15Z","timestamp":1787066415011,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004854","name":"St Antonius Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejso.2024.108487","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:22:52Z","timestamp":1718292172000},"page":"108487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8927-6509","authenticated-orcid":false,"given":"Paulien","family":"Rauwerdink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-4054","authenticated-orcid":false,"given":"Vincent C.J.","family":"van de Vlasakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.E.","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin H.","family":"Herbschleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan M.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M.J.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela G.","family":"Raicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment J.R.","family":"Huysentruyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-4351","authenticated-orcid":false,"given":"Erik J.R.J.","family":"van der Hoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-5866","authenticated-orcid":false,"given":"Joost","family":"Nederend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifka Y.M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6420","authenticated-orcid":false,"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-5521","authenticated-orcid":false,"given":"Remond J.A.","family":"Fijneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Constantinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim W.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-9477","authenticated-orcid":false,"given":"Simon W.","family":"Nienhuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Lurvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H.J.T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"2017","key":"10.1016\/j.ejso.2024.108487_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer \u2013 beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","article-title":"Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study: colorectal PM: incidence & associated factors","volume":"47","author":"Lurvink","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108487_bib4","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2024.108487_bib5","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1245\/s10434-021-10190-z","article-title":"Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study","volume":"28","author":"Bakkers","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases","volume":"32","author":"van der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"issue":"2016","key":"10.1016\/j.ejso.2024.108487_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","article-title":"Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study","volume":"65","author":"Razenberg","year":"2016","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2024.108487_bib8","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"Rovers","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2024.108487_bib11","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/annonc\/mdq762","article-title":"Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy","volume":"22","author":"Klaver","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108487_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41575-020-0314-8","article-title":"Modern therapeutic approaches for the treatment of malignant liver tumours","volume":"17","author":"Petrowsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ejso.2024.108487_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jamcollsurg.2019.12.024","article-title":"Aggressive multimodal treatment and metastatic colorectal cancer survival","volume":"230","author":"Zhang","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ejso.2021.12.004","article-title":"Treatment of metachronous colorectal cancer metastases in The Netherlands: a population-based study","volume":"48","author":"Meyer","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a novel approach for intraperitoneal drug delivery and the related device","volume":"26","author":"Sola\u00df","year":"2012","journal-title":"Surg Endosc"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg Endosc"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib20","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","article-title":"Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"20","author":"Blanco","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib21","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejso.2020.08.020","article-title":"Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification? Current practice of PIPAC","volume":"47","author":"Sgarbura","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108487_bib24","first-page":"1","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework","author":"Baggaley","year":"2022","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.ejso.2024.108487_bib25","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","article-title":"Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC)","volume":"28","author":"Rovers","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2024.108487_bib26","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/pp-2021-0108","article-title":"The ISSPP PIPAC database: design, process, access, and first interim analysis","volume":"6","author":"Mortensen","year":"2021","journal-title":"Pleura and Peritoneum"},{"issue":"12","key":"10.1016\/j.ejso.2024.108487_bib28","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1245\/s10434-023-13941-2","article-title":"Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA","volume":"30","author":"Raoof","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.108487_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/pp-2023-0008","article-title":"UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228)","volume":"8","author":"Kyle","year":"2023","journal-title":"Pleura and Peritoneum"},{"key":"10.1016\/j.ejso.2024.108487_bib30","article-title":"Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study","author":"Graversen","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2020-044811","volume":"11","author":"Lurvink","year":"2021","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.ejso.2024.108487_bib32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"2022","key":"10.1016\/j.ejso.2024.108487_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2021.12.009","article-title":"UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients","volume":"162","author":"Hulshof","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2024.108487_bib34","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030408","article-title":"Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II","volume":"9","author":"Rovers","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejso.2024.108487_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108487_bib40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1245\/s10434-016-5108-4","article-title":"In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC)","volume":"23","author":"Kakchekeeva","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108487_bib41","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","article-title":"Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis","volume":"45","author":"Willaert","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108487_bib42","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. November 27, 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed February 2, 2022."},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib43","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","article-title":"New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma","volume":"19","author":"Lencioni","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2024.108487_bib45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/bjs.10989","article-title":"Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery","volume":"106","author":"van \u2019t Sant","year":"2019","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/pp-2016-0011","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal Regression Grading Score (PRGS)","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura and Peritoneum"},{"issue":"7","key":"10.1016\/j.ejso.2024.108487_bib47","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/his.13829","article-title":"Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis","volume":"74","author":"Solass","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2024.108487_bib48","volume":"2021","year":"2021"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejso.2019.03.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study","volume":"47","author":"Siebert","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2024.108487_bib50","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1245\/s10434-022-11577-2","article-title":"Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study","volume":"29","author":"Taibi","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.ejso.2024.108487_bib51","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000343943","article-title":"Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer","volume":"87","author":"Yoshida","year":"2013","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib54","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","article-title":"Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin","volume":"21","author":"Eveno","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen","year":"2014","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2024.108487_bib56","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1245\/s10434-016-5211-6","article-title":"Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC","volume":"23","author":"Simkens","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","volume":"126","author":"Larsen","year":"2022","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ejso.2024.108487_bib59","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2024.108487_bib60","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.2011.19","article-title":"BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer","volume":"104","author":"Yokota","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2018.11.007","article-title":"Review: pathology and its clinical relevance of mucinous appendiceal neoplasms and pseudomyxoma peritonei","volume":"18","author":"Legu\u00e9","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.soc.2018.02.002","article-title":"Imaging for peritoneal metastases","volume":"27","author":"Low","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.ejso.2024.108487_bib64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jso.20049","article-title":"Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement","volume":"86","author":"De Bree","year":"2004","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11547-016-0682-x","article-title":"Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis","volume":"122","author":"Laghi","year":"2017","journal-title":"Radiol Medica"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08168-x","article-title":"Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial","volume":"21","author":"Engbersen","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib67","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","article-title":"Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41416-022-01748-z","article-title":"Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging","volume":"127","author":"Strating","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cpet.2023.02.003","article-title":"Fibroblast activation protein inhibitor-PET imaging in colorectal cancer","volume":"18","author":"Strating","year":"2023","journal-title":"Pet Clin"},{"issue":"4","key":"10.1016\/j.ejso.2024.108487_bib70","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"Demtr\u00f6der","year":"2016","journal-title":"Color Dis"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","article-title":"Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial","volume":"28","author":"Lurvink","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108487_bib72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/pp-2022-0102","article-title":"Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"7","author":"Sgarbura","year":"2022","journal-title":"Pleura and Peritoneum"},{"issue":"10","key":"10.1016\/j.ejso.2024.108487_bib74","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/bjs.11206","article-title":"Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy","volume":"106","author":"Ubink","year":"2019","journal-title":"Br J Surg"},{"issue":"11","key":"10.1016\/j.ejso.2024.108487_bib75","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","article-title":"The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)","volume":"47","author":"van de Vlasakker","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108487_bib76","doi-asserted-by":"crossref","first-page":"S724","DOI":"10.1016\/j.annonc.2022.07.550","article-title":"412P Phase I study of intraperitoneal irinotecan in combination with standard systemic chemotherapy in patients with extensive peritoneal metastases of colorectal origin: the INTERACT trial","volume":"33","author":"Van Eerden","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108487_bib77","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1245\/s10434-023-13150-x","article-title":"Comparison of neoadjuvant systemic chemotherapy protocols for the curative-intent management of peritoneal metastases from colorectal cancer, regarding morphological response, pathological response, and long-term outcomes: a retrospective study","volume":"30","author":"Fanget","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108487_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-023-04434-5","article-title":"Intraperitoneal paclitaxel combined with FOLFOX\/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study","volume":"38","author":"Murono","year":"2023","journal-title":"Int J Colorectal Dis"},{"issue":"23","key":"10.1016\/j.ejso.2024.108487_bib79","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T14:20:38Z","timestamp":1737296438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324005390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0748798324005390"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108487","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108487"}}